All Title Author
Keywords Abstract

PLOS ONE  2012 

Small Mutations in Bordetella pertussis Are Associated with Selective Sweeps

DOI: 10.1371/journal.pone.0046407

Full-Text   Cite this paper   Add to My Lib

Abstract:

Bordetella pertussis is the causative agent of pertussis, a highly contagious disease of the human respiratory tract. Despite high vaccination coverage, pertussis has resurged and has become one of the most prevalent vaccine-preventable diseases in developed countries. We have proposed that both waning immunity and pathogen adaptation have contributed to the persistence and resurgence of pertussis. Allelic variation has been found in virulence-associated genes coding for the pertussis toxin A subunit (ptxA), pertactin (prn), serotype 2 fimbriae (fim2), serotype 3 fimbriae (fim3) and the promoter for pertussis toxin (ptxP). In this study, we investigated how more than 60 years of vaccination has affected the Dutch B. pertussis population by combining data from phylogeny, genomics and temporal trends in strain frequencies. Our main focus was on the ptxA, prn, fim3 and ptxP genes. However, we also compared the genomes of 11 Dutch strains belonging to successful lineages. Our results showed that, between 1949 and 2010, the Dutch B. pertussis population has undergone as least four selective sweeps that were associated with small mutations in ptxA, prn, fim3 and ptxP. Phylogenetic analysis revealed a stepwise adaptation in which mutations accumulated clonally. Genomic analysis revealed a number of additional mutations which may have a contributed to the selective sweeps. Five large deletions were identified which were fixed in the pathogen population. However, only one was linked to a selective sweep. No evidence was found for a role of gene acquisition in pathogen adaptation. Our results suggest that the B. pertussis gene repertoire is already well adapted to its current niche and required only fine tuning to persist in the face of vaccination. Further, this work shows that small mutations, even single SNPs, can drive large changes in the populations of bacterial pathogens within a time span of six to 19 years.

References

[1]  Lavine JS, King AA, Bjornstad ON (2011) Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc Natl Acad Sci U S A 108: 7259–7264.
[2]  Martcheva M, Bolker BM, Holt RD (2008) Vaccine-induced pathogen strain replacement: what are the mechanisms? J R Soc Interface 5: 3–13.
[3]  Restif O, Grenfell BT (2007) Vaccination and the dynamics of immune evasion. J R Soc Interface 4: 143–153.
[4]  Lipsitch M, O'Hagan JJ (2007) Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 4: 787–802.
[5]  Octavia S, Maharjan RP, Sintchenko V, Stevenson G, Reeves PR, et al. (2011) Insight into evolution of Bordetella pertussis from comparative genomic analysis: evidence of vaccine-driven selection. Mol Biol Evol 28: 707–715.
[6]  Mooi FR (2010) Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 10: 36–49.
[7]  Mooi FR, van Loo IH, King AJ (2001) Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 7: 526–528.
[8]  Kallonen T, He Q (2009) Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines 8: 863–875.
[9]  Berbers GA, de Greeff SC, Mooi FR (2009) Improving pertussis vaccination. Hum Vaccin 5: 497–503.
[10]  He Q, Mertsola J (2008) Factors contributing to pertussis resurgence. Future Microbiol 3: 329–339.
[11]  Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J (2004) Pertussis in Poland. Int J Epidemiol 33: 358–365.
[12]  Moerman L, Leventhal A, Slater PE, Anis E, Yishai R, et al. (2006) The re-emergence of pertussis in Israel. Isr Med Assoc J 8: 308–311.
[13]  Hozbor D, Mooi F, Flores D, Weltman G, Bottero D, et al. (2009) Pertussis epidemiology in Argentina: trends over 2004–2007. J Infect 59: 225–231.
[14]  Spokes PJ, Quinn HE, McAnulty JM (2010) Review of the 2008–2009 pertussis epidemic in NSW: notifications and hospitalisations. N S W Public Health Bull 21: 167–173.
[15]  Hall-Baker PA, Nieves E, Jajosky RA, Adams DA, Sharp P, et al. (2010) Summary of Notifiable Diseases—United States, 2008. Morbidity and Mortality Weekly Report (MMWR) 57: 1–94.
[16]  Rendi-Wagner P, Tobias J, Moerman L, Goren S, Bassal R, et al. (2010) The seroepidemiology of Bordetella pertussis in Israel–Estimate of incidence of infection. Vaccine 28: 3285–3290.
[17]  Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E (2009) Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS 117: 912–922.
[18]  Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, et al. (2005) The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133: 159–171.
[19]  Cherry JD (2005) The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115: 1422–1427.
[20]  de Greeff SC, Mooi FR, Schellekens JF, de Melker HE (2008) Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27: 218–223.
[21]  de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, et al. (2010) Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50: 1339–1345.
[22]  McIntyre P, Wood N (2009) Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis 22: 215–223.
[23]  Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, et al. (1998) Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66: 670–675.
[24]  Maharjan RP, Gu C, Reeves PR, Sintchenko V, Gilbert GL, et al. (2008) Genome-wide analysis of single nucleotide polymorphisms in Bordetella pertussis using comparative genomic sequencing. Res Microbiol 159: 602–608.
[25]  Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P, et al. (2010) Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 11: 627.
[26]  Advani A, Gustafsson L, Ahren C, Mooi FR, Hallander HO (2011) Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 29: 3438–3442.
[27]  Kallonen T, Grondahl-Yli-Hannuksela K, Elomaa A, Lutynska A, Fry NK, et al. (2011) Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol
[28]  King AJ, van Gorkom T, van der Heide HG, Advani A, van der Lee S (2010) Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics 11: 64.
[29]  King AJ, van Gorkom T, Pennings JL, van der Heide HG, He Q, et al. (2008) Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics 9: 311.
[30]  Bouchez V, Caro V, Levillain E, Guigon G, Guiso N (2008) Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One 3: e2437.
[31]  Heikkinen E, Kallonen T, Saarinen L, Sara R, King AJ, et al. (2007) Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One 2: e904.
[32]  Cummings CA, Brinig MM, Lepp PW, van de Pas S, Relman DA (2004) Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J Bacteriol 186: 1484–1492.
[33]  Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M (2010) Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol 17: 807–812.
[34]  Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernandez J, et al. (2007) Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 14: 1490–1498.
[35]  Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, et al. (2004) Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 22: 2122–2128.
[36]  Watanabe M, Nagai M (2002) Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J Health Sci 48: 560–564.
[37]  King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, et al. (2001) Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147: 2885–2895.
[38]  Petersen RF, Dalby T, Dragsted DM, Mooi FR, Lambertsen L (2012) Temporal trends in the Bordetella pertussis populations in Denmark in the period 1949–2010. Emerg Infect Dis In press.
[39]  Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15: 1206–1213.
[40]  Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, et al. (2012) Newly Emerging Clones of Bordetella pertussis Carrying prn2 and ptxP3 Alleles Implicated in Australian Pertussis Epidemic in 2008–2010. J Infect Dis 205: 1220–1224.
[41]  van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, et al. (2011) SNP-Based Typing: A Useful Tool to Study Bordetella pertussis Populations. PLoS One 6: e20340.
[42]  Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, et al. (2012) Prevalence and Genetic Characterization of Pertactin-Deficient Bordetella pertussis in Japan. PLoS One 7: e31985.
[43]  Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, et al. (2009) First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 27: 6034–6041.
[44]  van Loo IH, Heuvelman KJ, King AJ, Mooi FR (2002) Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol 40: 1994–2001.
[45]  Hunter PR, Gaston MA (1988) Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol 26: 2465–2466.
[46]  Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, et al. (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35: 32–40.
[47]  Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18: 1851–1858.
[48]  Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, et al. (2005) Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 1: e45.
[49]  Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO (2007) Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS 115: 736–742.
[50]  Tsang RS, Lau AK, Sill ML, Halperin SA, Van Caeseele P, et al. (2004) Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J Clin Microbiol 42: 5364–5367.
[51]  Fry NK, Neal S, Harrison TG, Miller E, Matthews R, et al. (2001) Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 69: 5520–5528.
[52]  Litt DJ, Neal SE, Fry NK (2009) Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol 47: 680–688.
[53]  van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, et al. (2005) Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol 43: 2837–2843.
[54]  Schouls LM, van der Heide HG, Vauterin L, Vauterin P, Mooi FR (2004) Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol 186: 5496–5505.
[55]  Willems R, Paul A, van der Heide HG, ter Avest AR, Mooi FR (1990) Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J 9: 2803–2809.
[56]  Cummings CA, Bootsma HJ, Relman DA, Miller JF (2006) Species- and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J Bacteriol 188: 1775–1785.
[57]  Han HJ, Kuwae A, Abe A, Arakawa Y, Kamachi K (2011) Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS One 6: e17797.
[58]  de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR (2011) Pertussis: a matter of immune modulation. FEMS Microbiol Rev 35: 441–474.
[59]  Bedford T, Cobey S, Pascual M (2011) Strength and tempo of selection revealed in viral gene genealogies. BMC Evol Biol 11: 220.
[60]  Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, et al. (2012) Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol
[61]  van Loo IH, van der Heide HG, Nagelkerke NJ, Verhoef J, Mooi FR (1999) Temporal trends in the population structure of Bordetella pertussis during 1949–1996 in a highly vaccinated population. J Infect Dis 179: 915–923.
[62]  Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, et al. (2007) Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25: 391–398.
[63]  Panina EM, Mattoo S, Griffith N, Kozak NA, Yuk MH, et al. (2005) A genome-wide screen identifies a Bordetella type III secretion effector and candidate effectors in other species. Mol Microbiol 58: 267–279.
[64]  French CT, Panina EM, Yeh SH, Griffith N, Arambula DG, et al. (2009) The Bordetella type III secretion system effector BteA contains a conserved N-terminal motif that guides bacterial virulence factors to lipid rafts. Cell Microbiol 11: 1735–1749.
[65]  Zhang S, Xu Y, Zhou Z, Wang S, Yang R, et al. (2011) Complete genome sequence of Bordetella pertussis CS, a Chinese pertussis vaccine strain. J Bacteriol 193: 4017–4018.
[66]  Yuk MH, Harvill ET, Miller JF (1998) The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol Microbiol 28: 945–959.
[67]  Kerr JR, Rigg GP, Matthews RC, Burnie JP (1999) The Bpel locus encodes type III secretion machinery in Bordetella pertussis. Microb Pathog 27: 349–367.
[68]  Stibitz S (2007) The bvg Regulon. Bordetella Molecular Microbiology 1: 47–67.
[69]  Hijnen M, de Voer R, Mooi FR, Schepp R, Moret EE, et al. (2007) The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine 25: 5902–5914.
[70]  He Q, Makinen J, Berbers G, Mooi FR, Viljanen MK, et al. (2003) Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? laJ Infect Dis 187: 1200–1205.
[71]  Williamson P, Matthews R (1996) Epitope mapping the Fim2 and Fim3 proteins of Bordetella pertussis with sera from patients infected with or vaccinated against whooping cough. FEMS Immunol Med Microbiol 13: 169–178.
[72]  Andreasen C, Carbonetti NH (2009) Role of neutrophils in response to Bordetella pertussis infection in mice. Infect Immun 77: 1182–1188.
[73]  Andreasen C, Carbonetti NH (2008) Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect Immun 76: 5139–5148.
[74]  Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET (2005) Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 115: 3594–3601.
[75]  Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI (2007) Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun 75: 1713–1720.
[76]  Carbonetti NH, Artamonova GV, Mays RM, Worthington ZE (2003) Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun 71: 6358–6366.
[77]  van Gent M, van Loo IH, Heuvelman KJ, de Neeling AJ, Teunis P, et al. (2011) Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One 6: e18014.
[78]  Streefland M, van de Waterbeemd B, Happe H, van der Pol LA, Beuvery EC, et al. (2007) PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease. Vaccine 25: 2994–3000.

Full-Text

comments powered by Disqus